The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia by Rio-Machin, A. et al.
unchanged over this period when adjusted for age, stage at
diagnosis, time from diagnosis to transplant and disease status
at transplant. VRD has become the most common pre-
transplant induction regimen after 2010. Only, half of patients
are placed on post-transplant treatment at day 100 after AHCT,
with lenalidomide as the most frequently used agent. Counter-
intuitively, we did not see an increase in the use of maintenance
treatment in the most recent period. Despite these impressive
gains in the field, progression of MM remains the most frequent
cause of death.
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Recurrent chromosomal translocations are common initiation
events and have provided important insights into the pathogen-
esis of AML, paving the way for the introduction of novel targeted
therapies. However, clinical outcomes, in particular for patients
with adverse cytogenetic features remain suboptimal. The
chromosomal translocation t(7;11)(p15, p15), encoding the fusion
protein NUP98-HOXA9 (NHA9), is a rare poor risk cytogenetic
event in AML associated with a particularly poor prognosis. NHA9
brings the FG repeat-rich portion of the nucleoporin NUP98
upstream of the homeodomain and PBX heterodimerization
domains of HOXA9, and acts as oncogenic transcription factor.1
The pathogenic events underlying NHA9 remain poorly under-
stood and herein, we aim to characterize the downstream
mediators of this oncoprotein by determining the effects of the
fusion using human cellular models.
We set out initially to compare the DNA binding sites of NHA9,
HOXA9 and NUP98, by forced expression of these genes alone or
the corresponding fusion gene by retroviral transduction of
HEK93FT cell line and cord blood-isolated human hematopoietic
progenitors (hHP). ChIP-seq analysis in the HEK293FT cellular
model identified 4471 significant genomic regions (false discovery
rate (FDR) o0.05) as target sites of the fusion protein, all located
within –5/+ kb from the annotated transcription start site (TSS)
(Supplementary Figure S1A). They correspond to 1368 genes and
17 miRNAs (Supplementary Table S1) of which 399 genes were
also shown to be common targets of HOXA9 and 4 of NUP98
(Figure 1a, Supplementary Table S2, Supplementary Figures S1C–
D) (Supplementary methods) (Data deposited in GEO http://www.
ncbi.nlm.nih.gov/geo/, accession number: GSE62587). Ingenuity
pathway analysis of the NHA9 target series demonstrated a
significant enrichment of pathways associated with tumorigenesis
and leukemic differentiation (Supplementary Figure S1B).
We next performed a detailed sequence analysis of the NHA9
binding sites using the MEME-ChIP algorithm and detected a
significant overlap with binding of several HOX genes, including
HOXA9, supporting a role for this homeodomain in the DNA
binding of NHA9. Strikingly, NHA9 sites were enriched for a novel
binding motif, CA/gTTT, that was present in one-third (n= 1421) of
all NHA9 ChIP-seq regions (Supplementary Table S3). This motif
had not been previously associated with any known transcription
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factor and was not observed in wild type HOXA9 or NUP98 binding
site experiments, suggesting that it is specific to NHA9 DNA
binding. MEME-ChIP (SpaMO) was used to identify significant
co-occurrences of other known DNA binding motifs with this
novel NHA9 DNA binding motif. Binding motifs corresponding to
12 transcription factors, including other HOX family proteins such
as HOXB7 or HOXD11, were found to be overrepresented within
the region adjacent to CA/gTTT (Supplementary Table S4),
Figure 1. For caption see next page.
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suggesting a possible functional cooperation with the fusion
oncoprotein.
As the NHA9 target motifs are preferentially located more than
1 kb upstream/downstream of the TSS (Supplementary Figure
S1A), we reasoned that NHA9 binding may coincide with particular
enhancer elements. A similar distribution was also found for the
identified HOXA9 target regions whereas NUP98 binding sites were
mostly located within promoters, both in agreement with previous
studies.2,3 We selected eight leukemia-related genes (MEIS1,
HOXA9, PBX3, MET, BRAF, AF9, PTEN and NF1) identified as part
of our NHA9 ChIP-seq experiments, for locus specific qChIP
studies. A significant enrichment of H3K4me1, a chromatin mark
that predicts poised and active enhancers, and RNA Polymerase II
(PolII), which is consistent with the presence of the active form of
the enhancers,4,5 was shown within the NHA9 binding sites
upstream of the eight genes (Figure 1b and Supplementary
Figure S1E). NHA9 expression levels were demonstrated to be
comparable in our two cellular models (HEK293FT and hHP)
(Supplementary Figure S1G). Accordingly, we validated the ChIP-
seq results in the HEK293FT model (Supplementary Figure S1F)
using the same set of eight NHA9 target genes and also
demonstrated binding of NHA9 to the eight enhancers in our
second model system of NHA9-expressing hHP cells (Figure 1c),
allowing us to confirm these findings in primary human
hematopoiesis.
We next focused attention on the transcription factors MEIS1,
HOXA9 and PBX3, as their overexpression is significantly related to
adverse prognosis in AML (The Cancer Genome Atlas;6
Supplementary Figure S1H) and were previously reported to drive
leukemogenesis through the formation of a transcriptional
activator complex.7 To test the importance of these three
transcription factors in NHA9 pathogenesis, we completed
reporter assays in HEK293FT cells by cloning the identified
enhancers of MEIS1, HOXA9 or PBX3 into a luciferase reporter
vector. A significant 1.6–2.8 fold induction in luciferase activity was
observed when NHA9 was co-expressed for all three enhancers,
indicating a direct induction of MEIS1, HOXA9 and PBX3 expression
through the NHA9 interaction with their corresponding regulatory
regions (Figure 1d) (Supplementary Methods). This observation
was accompanied by upregulation of all three transcription factors
and of three of their known target genes (MYB, MEF2C and FLT3)7
in NHA9-expressing hHP cells (Figure 1e and Supplementary
Figure S1I). Gene Expression Profiling performed in three
independent NHA9-expressing hHP clones and AMLs from five
patients with t(7;11)(p15,p15), confirmed MEIS1-HOXA9-PBX3 over-
expression and it was further validated by RT-qPCR analysis in
three additional NHA9 primary samples (Supplementary
Figure S2A). These observations suggested that the NHA9-
expressing hHP cells can be sensitive to HXR9, a specific peptide
inhibitor of HOXA9 and PBX3 interaction that leads to disruption
of the MEIS1-HOXA9-PBX3 complex.8 We tested this hypothesis by
treating these cells with HXR9 that resulted in a selective decrease
in their viability (Figure 1f and Supplementary Figure S2B–D)
(Supplementary Methods) without affecting cell differentiation
(data not shown), therefore confirming the relevance of these
downstream mediators in driving the oncogenic activity of NHA9.
In order to explore other mechanisms driving NHA9 pathogen-
esis and to better understand its role in transcriptional regulation,
we interrogated our ChIP-seq and gene expression profiling data,
which revealed both activation and repression of gene expression
Figure 1. NUP98-HOXA9 binds to enhancers of genes related to leukemogenesis (a) Venn diagrams of NHA9, HOXA9 and NUP98 target genes
identified by ChIP-seq experiments on HEK293FT human models and located within +5/− 5 kb of an annotated Transcrption Start Site (TSS).
Significant ChIP-seq peaks were established at FDR⩽ 5%. (b) H3K4me1 qChIP fold enrichment in the selected NHA9 target regions using anti-
H3K4me1 antibody. The MEIS1 promoter region was used as a negative control. The average of three experiments is shown. Error bars
represent s.e.m. (c) NHA9 qChIP fold enrichment on the eight selected NHA9 target enhancer regions using anti-FLAG antibody in the NHA9-
expressing hHP cellular model. The average of three experiments is shown. Error bars represent s.e.m. (d) Luciferase assay was performed to
analyze the role of NHA9 in regulating the expression of HOXA9, PBX3 and MEIS1. The luciferase constructs containing the enhancer region
(using pGL3-Promoter vector, Promega Biotech Ibérica S.L) of HOXA9, PBX3 and MEIS1 were co-transfected into HEK293FT cells with the
expression vector pMSCV-NHA9, together with Renilla vector for the purpose of normalization. Luciferase activity was determined 48 h after
reporter plasmid transfection in all cases. A significant increase in luciferase activity induced by NHA9 expression was observed in each case,
confirming a direct increase of MEIS1, HOXA9 and PBX3 expression through NHA9 interaction with their corresponding enhancer regions. Data
are presented as the mean value from two separate experiments with n= 3 for each experiment. Error bars represent s.e.m. (e) Expression
analysis by qRT-PCR of MEIS1, HOXA9 and PBX3 in the NHA9-expressing hHP cellular model. The expression of the endogenous human
housekeeping gene GAPDH was used to normalize the data, which are expressed as the mean of 2−ΔCt values obtained for each sample after
normalization based on the hHP-empty vector model. (f) Analysis of the hHP-NHA9 response to HXR9 and CXR9 (control) peptides. hHP-NHA9
cells were plated in 96-well plates in triplicate and exposed to 13 µM of HXR9/CXR9. Cell viability was assessed at different time points. Average
normalized optical density (OD) values of three independent experiments are shown. Statistical significance for relative enrichment and
proliferation was determined at Po0.05 (*), Po0.01 (**) and Po0.001 (***), using a t-test with Bonferroni correction. N.S corresponds to non-
significant comparisons. Error bars represent s.e.m.
Figure 2. NUP98-HOXA9 has an activator-repressor role in transcriptional regulation driven by p300 and HDAC1 interactions. (a) We applied
gene set enrichment analysis (GSEA) to test for enrichment of NHA9 ChIP-seq target gene set among differentially expressed genes using
expression array data from hHP-NHA9 cellular model (left panel) and five NHA9 primary samples (right panel). Genes were ranked based on
the limma-moderated t statistic. After Kolmogorov–Smirnoff testing, those gene sets with FDR o0.25, a well-established cutoff for the
identification of biologically relevant gene sets, were considered enriched (b) Analysis of NHA9 and p300/HDAC1 interactions by co-
immunoprecipitation. HEK293FT cells were transfected with pMSCV-NUP98-HOXA9 or pMSCV-empty vectors. Forty-eight hours post-
transfection, the immunoprecitpitation was performed using anti-p300 and anti-HDAC1 antibodies and the proteins were analyze by
immunoblotting using anti-FLAG antibody. Endogenous GAPDH protein levels were used as a loading control. (c, d) qChIP fold enrichment of
p300 and HDAC1 in the regulatory regions of four upregulated (c) and four downregulated (d) target genes of NHA9. The average of three
experiments showed the binding, along with the fusion protein, of p300 and HDAC1 to the regulatory regions of the overexpressed and
downregulated NHA9 target genes, respectively. (e) Analysis of the hHP-NHA9 response to HDAC inhibitors. Cells were exposed for 72 h to
serial dilutions of panobinostat (LBH589) followed by the addition of WST-1 to assess cell viability. The average normalized optical density
(OD) values are shown compared to vehicle. Statistical significance for relative enrichment and proliferation was determined at Po0.05 (*),
Po0.01 (**) and Po0.001 (***), using a t-test with Bonferroni correction. N.S corresponds to non-significant comparisons. Error bars
represent s.e.m.
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induced by this fusion oncoprotein (Figure 2a). The cooperation of
MLL1 and CRM1 with NHA9 in the upregulation of some target
genes has been shown recently by Xu et al.,9,10 which was also
supported by comparing NHA9 target genes identified in our
ChIP-seq experiments with MLL1 and CRM1 targets. We found that
25% and 35% of NHA9 target genes were also in common with
MLL1 and CRM1 target genes, respectively (Supplementary
Figure S2E). Notably, 151 target genes, including MEIS1 and
HOXA9, were shared by all three proteins (NHA9, MLL1 and CRM1),
suggesting a possible cooperation among these transcription
factors in NHA9-driven leukemias. It has also been reported that
NUP98, through its FG repeat domain, may interact with
transcriptional activator p300 and repressor HDACs,11 allowing
us to postulate that transcriptional effects of NHA9 in enhancers
could be mediated by these regulators. We first demonstrated
NHA9 binding to both p300 and HDAC1 by co-immunoprecipitation
experiments (Figure 2b) (Supplementary Methods) and went on to
examine their binding potential in a panel of eight regulatory
regions of NHA9 target genes (four upregulated and four down-
regulated target genes) in the presence of the fusion protein by
qChIP. These experiments demonstrated selective binding of p300
to the regulatory regions of the upregulated genes MEIS1, HOXA9,
PBX3 and AFF3 (Figure 2c), and of HDAC1 to the downregulated
genes BIRC3, SMAD1, FILIP1L and PTEN (Figure 2d). Altogether this
data suggests that p300 and HDAC1 are selectively recruited by
NHA9 at enhancer regions to modulate the expression of genes
involved in leukemogenesis.
As the interaction of NHA9 with HDAC1/2 was validated by
mass spectrometry analysis using the NHA9-expressing
HEK293FT model (Proteomics data have been deposited on
the ProteomeXchange Consortium via the PRIDE partner reposi-
tory, data set identifier PXD001828) (Supplementary Methods), we
had a molecular rationale for testing HDAC inhibitors
(HDACi) in NHA9 AML. We assessed the sensitivity of the hHP-
NHA9 model to the pan-HDACi LBH589 (Panobinostat) and
observed a strong inhibitory effect that was significantly higher
(IC50hHP-NHA9≈4 nM) than its inhibitory effect in MLL-AF9-
expressing (IC50hHP-MLL_AF9≈30 nM) or AML1-ETO-expressing
(IC50hHP-AML1_ETO≈200 nM) hHP cells,12,13 where the efficacy of this
component has been already established14,15 (Figure 2e). Accord-
ingly, treatment with low doses (4 nM) of LBH589 completely
abrogated the ability of hHP-NHA9 cells to form colonies in the
CFC assay (Supplementary Figure S2F) and significantly induced
apoptosis within 24 h (4 nM and 30 nM doses), whereas LBH589
had no effect at the same doses on the empty vector control hHP
cells (Supplementary Figure S2G). It has to be noted that LBH589
did not induce differentiation in NHA9-expressing cells as no
significant changes in the number of CD11b positive cells were
observed by flow cytometry analysis post treatment (data not
shown). These observations are in accordance with a recent report
suggesting the combination of COX or DNMT inhibitors with
HDACi for treatment of NHA9 AML patients,16 however in this
study we identified the molecular rationale for HDACi therapy as
well as a panel of target genes downstream of NHA9 that can be
used as biomarkers for response to this treatment. Furthermore,
our hHP-NH9A cellular model showed sensitivity to markedly
lower concentrations of LBH589 (4 nM) than the recommended
doses in preclinical studies and Multiple Myeloma Clinical
Trials,17,18 indicating that LBH589 could be safely used as novel
targeted therapy for the treatment of NH9A AML patients.
However, the biological consequences of this therapy, as well as
the best dosage-time relation for the translation into clinics need
to be further investigated.
In summary, NHA9 deregulates the expression of key leukemic
genes, including MEIS1-HOXA9-PBX3 complex, through the enhancer
binding and the direct interaction of the fusion protein with HDAC
and p300 transcriptional regulators. The oncogenic effects of NHA9
can be overcome by HDACi treatment, demonstrating a significant
inhibitory effects against NHA9-driven leukemic cells and suggesting
a novel approach to treatment of this high-risk group of patients.
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Philadelphia-negative neutrophilic leukemias—atypical chronic
myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL),
MDS/MPNu (myelodysplastic/myeloproliferative neoplasm, unclas-
sifiable), and MPNu (myeloproliferative neoplasm, unclassifiable)
—are rare hematologic neoplasms characterized by leukocytosis, a
hypercellular bone marrow comprised predominantly of granulo-
cytic cells, absence of the Philadelphia chromosome (t(9;22); BCR-
ABL1), and absence of PDGFRA/B or FGFR1 gene rearrangements.
Occasional cases of CNL1 and MDS/MPNu,2 as well as a majority of
aCML cases, exhibit non-specific cytogenetic abnormalities3 or the
JAK2 V617F mutation,4 revealing their clonal nature. The primary
genetic basis of these leukemias was unknown until recent work
by Maxson et al.,5 which highlighted mutations in CSF3R as key
leukemogenic drivers in ~ 60% of patients with aCML or CNL.
Subsequent studies found CSF3R mutations in a majority of
patients with CNL and only in a minority of patients with aCML,6
with parallel studies of aCML revealing the presence of recurrent
SETBP1 and ETNK1 mutations.7,8 Despite these discoveries, knowl-
edge of the full genetic landscape of Philadelphia-negative
neutrophilic leukemias remains incomplete. To identify and
characterize additional mutations contributing to the pathogen-
esis of these malignancies, we performed whole exome sequen-
cing (WES) on 116 Philadelphia-negative neutrophilic leukemia
samples (Supplementary Materials and Methods).
We identified 4/116 samples harboring mutations in CCND2, the
gene encoding the cell cycle regulator cyclin D2. Of these four
samples, one was pathologically confirmed as MPNu, while
another was confirmed as MDS/MPNu (Supplementary Table 1).
Interestingly, all mutated samples harbored variants in codon 281,
with three samples possessing a P281S variant and the other
carrying a P281L variant (Supplementary Table 1). These changes
appeared to occur as heterozygous mutations and were present
only in patients lacking CSF3R mutations, with one sample (13-
00010) harboring a known pathogenic SETBP1 variant (I871T), and
another (14-00247) possessing an SRSF2 P95H variant. Two out of
four samples harbored a TET2mutation (other observed mutations
in Supplementary Table 2). All mutations with additional available
DNA were confirmed by Sanger sequencing (Supplementary
Figure 1).
To determine the potential incidence of CCND2 mutations in
other hematologic malignancies, we interrogated cohorts of
patients with AML (n= 239), BCR-ABL1-positive CML (CML;
n= 44), chronic myelomonocytic leukemia (CMML; n= 24), B-cell
acute lymphoblastic leukemia (B-ALL; n= 49), or T-ALL (n= 7) by
whole exome sequencing for the presence of variants in CCND2
(Supplementary Table 2). We identified three AML patients
harboring the same CCND2 variants (two P281S; one P281L), all
confirmed as somatic (Supplementary Table 3). These findings are
consistent with two recent reports of similar CCND2 mutations in
AML.9,10 No mutations in CCND2 were detected in patients with
CML, CMML, B-ALL or T-ALL (Supplementary Table 2). Taken
together, these results suggest the presence of CCND2 mutations
may unify a small but recurrent and selective subset of patients
with the molecularly heterogeneous myeloid malignancies of
Philadelphia-negative neutrophilic leukemias and AML.
Previous work examining a missense variant in CCND2 (T280A),
just one amino acid upstream of P281, demonstrated the variant
to confer resistance to degradation.11 To assess whether the
nearby variants identified in our patient cohort resulted in similar
protein accumulation, NIH-3T3 cell lines stably overexpressing
either empty vector, wild-type CCND2, or mutant CCND2 were
treated with cycloheximide to block protein translation, and
protein extracts from cells were analyzed by Western blotting
(Figure 1a). While a rapid reduction in cyclin D2 protein was
observed in cells overexpressing wild-type cyclin D2, this was not
observed in cells overexpressing the mutant constructs. Therefore,
CCND2 P281 variants result in the accumulation of degradation-
resistant cyclin D2.
Interestingly, the CCND2 T280A variant is also associated with
constitutively nuclear localization of the protein.11 Because of the
proximity of the CCND2 P281 variants to the previously reported
T280A variant, we hypothesized that CCND2 P281 variants would
be constitutively nuclear in their localization. While overexpressed
wild-type CCND2 exhibited predominantly nuclear localization
during G1 phase of the cell cycle and cytoplasmic staining during S
phase, CCND2 P281 variant protein remained predominantly
nuclear in its localization regardless of cell cycle phase (Figure 1b).
Quantification of mean pixel density in the nucleus confirmed
statistical significance of this difference (Po0.0001; Figure 1c).
Variants in cyclin D1 have been reported at analogous residues
to P281S and P281L of cyclin D2, exhibiting predominantly nuclear
localization and oncogenic properties.12 We therefore assessed
the transformative capacity of CCND2 P281 variants by generating
Ba/F3 cell lines stably overexpressing either wild-type CCND2,
CCND2 P281S or CCND2 P281L and removing IL-3 from their
growth medium to assess for growth factor independence. As
shown in Figure 2a, neither wild-type nor mutant CCND2
transformed Ba/F3 cells to IL-3-independent growth. However,
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